US20030191056A1 - Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins - Google Patents

Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins Download PDF

Info

Publication number
US20030191056A1
US20030191056A1 US10/117,109 US11710902A US2003191056A1 US 20030191056 A1 US20030191056 A1 US 20030191056A1 US 11710902 A US11710902 A US 11710902A US 2003191056 A1 US2003191056 A1 US 2003191056A1
Authority
US
United States
Prior art keywords
ttr
biologically active
active agent
peg
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/117,109
Inventor
Kenneth Walker
Fei Xiong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to US10/117,109 priority Critical patent/US20030191056A1/en
Assigned to AMGEN INC. reassignment AMGEN INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WALKER, KENNETH, XIONG, FEI
Publication of US20030191056A1 publication Critical patent/US20030191056A1/en
Application status is Abandoned legal-status Critical

Links